Contact
searchSearch
HMP Global

September 2013 - FRMC

Fulyzaq™ (crofelemer) - Oral Therapy Approved to Relieve Diarrhea in Patients with HIV/AIDS
09/19/2013
The FDA approved Fulyzaq™ (crofelemer) in December 2012 to relieve noninfectious diarrhea in adults with HIV or AIDS who are taking anti-retroviral therapy.
The FDA approved Fulyzaq™ (crofelemer) in December 2012 to relieve noninfectious diarrhea in adults with HIV or AIDS who are taking anti-retroviral therapy.
The FDA approved Fulyzaq™...
09/19/2013
First Report Managed Care
Functional Impact of Adverse Events Associated with Pain Medications
09/19/2013
Two phase 3 trials found that patients with moderate-to-severe chronic low back pain or osteoarthritis of the knee who experienced adverse events during the studies had problems associated with physical functioning, social functioning, mental...
Two phase 3 trials found that patients with moderate-to-severe chronic low back pain or osteoarthritis of the knee who experienced adverse events during the studies had problems associated with physical functioning, social functioning, mental...
Two phase 3 trials found that...
09/19/2013
First Report Managed Care
Hydromorphone Extended Release for Chronic Pain
09/19/2013
In clinical practice, patients with moderate-to-severe chronic pain received doses of hydromorphone extended release that were nearly 50% lower than the doses given to patients who were prescribed oxymorphone extended release or oxycodone...
In clinical practice, patients with moderate-to-severe chronic pain received doses of hydromorphone extended release that were nearly 50% lower than the doses given to patients who were prescribed oxymorphone extended release or oxycodone...
In clinical practice, patients...
09/19/2013
First Report Managed Care
Abuse and Misuse of Opioid Medications
09/19/2013
Opioid medications have been proven effective in treating chronic pain; however, they are also associated with misuse, abuse, and diversion. 
Opioid medications have been proven effective in treating chronic pain; however, they are also associated with misuse, abuse, and diversion. 
Opioid medications have been...
09/19/2013
First Report Managed Care
Phase 3 Trial of Cariprazine for Schizophrenia
09/19/2013
San Francisco—After 9 weeks of treatment, patients with schizophrenia who received 3 mg or 6 mg of cariprazine had significant improvements in Positive and Negative Syndrome Scale (PANSS) total score and Clinical Global Impressions-Severity...
San Francisco—After 9 weeks of treatment, patients with schizophrenia who received 3 mg or 6 mg of cariprazine had significant improvements in Positive and Negative Syndrome Scale (PANSS) total score and Clinical Global Impressions-Severity...
San Francisco—After 9 weeks of...
09/19/2013
First Report Managed Care
Follow-Up Visits after Hospital Discharge for Schizophrenia
09/19/2013
San Francisco—Within 30 days of hospital discharge, approximately one third of patients with schizophrenia who had Medicaid or private health insurance failed to have a follow-up visit, according to a retrospective, longitudinal cohort...
San Francisco—Within 30 days of hospital discharge, approximately one third of patients with schizophrenia who had Medicaid or private health insurance failed to have a follow-up visit, according to a retrospective, longitudinal cohort...
San Francisco—Within 30 days of...
09/19/2013
First Report Managed Care
Reduction in MADRS Total Score for Patients with MDD
09/19/2013
San Francisco—After 8 weeks of treatment, patients with major depressive disorder (MDD) who received 20 mg of vortioxetine had a significant reduction in Montgomery-Asberg Depression Rating Scale (MADRS) total score compared with patients who...
San Francisco—After 8 weeks of treatment, patients with major depressive disorder (MDD) who received 20 mg of vortioxetine had a significant reduction in Montgomery-Asberg Depression Rating Scale (MADRS) total score compared with patients who...
San Francisco—After 8 weeks of...
09/19/2013
First Report Managed Care
Improving Rates of Functional Response in Major Depressive Disorder
09/19/2013
San Francisco—Patients with major depressive disorder who received 80 mg or 120 mg of levomilnacipran sustained release had significant functional improvement and greater rates of functional response compared with a placebo group, according...
San Francisco—Patients with major depressive disorder who received 80 mg or 120 mg of levomilnacipran sustained release had significant functional improvement and greater rates of functional response compared with a placebo group, according...
San Francisco—Patients with...
09/19/2013
First Report Managed Care

Department

News Connection
Enrollment in Medicare Part D Subsidy Program and Cognition Skills
09/19/2013
Beneficiaries enrolled in Medicare Part D with limited income and resources are eligible for a low-income subsidy (LIS) cost-sharing and premium assistance.
Beneficiaries enrolled in Medicare Part D with limited income and resources are eligible for a low-income subsidy (LIS) cost-sharing and premium assistance.
Beneficiaries enrolled in...
09/19/2013
First Report Managed Care
News Connection
Health Status of Uninsured Adults with Potential Medicaid Eligibility under ACA
09/19/2013
In states that choose to expand Medicaid under provisions in the Patient Protection and Affordable Care Act (ACA), the program’s focus will shift from low-income pregnant women and children, very–low-income parents, and severely disabled to...
In states that choose to expand Medicaid under provisions in the Patient Protection and Affordable Care Act (ACA), the program’s focus will shift from low-income pregnant women and children, very–low-income parents, and severely disabled to...
In states that choose to expand...
09/19/2013
First Report Managed Care
FRMC Volume 21, Issue 3

Current Issue

September 2024
Volume 21
Issue 3
Current Issue
Issue Archive

What's Trending?

News
Biotechnology Initial Public Offerings Soar in 2013
02/13/2014
New York—After several poor years, the biotechnology industry rebounded in 2013 with 45 initial public offerings (IPOs) of biotechnology companies and more money flowing into the sector. It was the most activity in the sector since 2000, and...
New York—After several poor years, the biotechnology industry rebounded in 2013 with 45 initial public offerings (IPOs) of biotechnology companies and more money flowing into the sector. It was the most activity in the sector since 2000, and...
New York—After several poor...
02/13/2014
First Report Managed Care
News
Study: Pediatric Patients Benefit From PCMH Utilization
03/22/2017
Researchers argue that public funding efforts should be invested in improving the use of patient centered medical homes for children covered under public insurance, or those who have no insurance at all.
Researchers argue that public funding efforts should be invested in improving the use of patient centered medical homes for children covered under public insurance, or those who have no insurance at all.
Researchers argue that public...
03/22/2017
First Report Managed Care
News
High Deductible Health Plans Associated With No Change in Asthma Care
10/26/2021
Authors noted that enrollment in high deductible health plans “was associated with minimal or no reductions in controller medication use for children and adults and no change in asthma exacerbations,” suggesting a potential benefit from...
Authors noted that enrollment in high deductible health plans “was associated with minimal or no reductions in controller medication use for children and adults and no change in asthma exacerbations,” suggesting a potential benefit from...
Authors noted that enrollment in...
10/26/2021
First Report Managed Care
Cancer Screening Cessation for Older Adults
06/26/2013
There are many educational efforts designed to increase the rates of screening for cancer, which is an important part of standard medical care. However, the balance of the risks and benefits of screening are affected by situations such as...
There are many educational efforts designed to increase the rates of screening for cancer, which is an important part of standard medical care. However, the balance of the risks and benefits of screening are affected by situations such as...
There are many educational...
06/26/2013
First Report Managed Care
News
Mylan gets approval for generic Effexor XR
06/08/2011
06/08/2011
First Report Managed Care

Video Insights

Videos
Bridging the Gaps in Prior Authorization: Challenges, Solutions, and Collaboration for Better Patient Care
11/13/2024
David Sand, MD, MBA, chief medical officer at ZeOmega, discusses the challenges of prior authorization, emphasizing the need for transparency, evidence-based standards, collaboration between payers and providers, and the potential for...
David Sand, MD, MBA, chief medical officer at ZeOmega, discusses the challenges of prior authorization, emphasizing the need for transparency, evidence-based standards, collaboration between payers and providers, and the potential for...
David Sand, MD, MBA, chief...
11/13/2024
First Report Managed Care
Richard Lipton, MD
Videos
The Evolving Role of CGRP-targeting Therapies in Migraine Prevention
10/31/2024
Richard Lipton, MD, provides insights on the American Headache Society’s position statement update on calcitonin gene-related peptide (CGRP)-targeting therapies as a first-line option for the prevention of migraine.
Richard Lipton, MD, provides insights on the American Headache Society’s position statement update on calcitonin gene-related peptide (CGRP)-targeting therapies as a first-line option for the prevention of migraine.
Richard Lipton, MD, provides...
10/31/2024
First Report Managed Care
Alexander Spira, MD, PhD
Videos
Unmet Needs in the Treatment and Management of Non–Small Cell Lung Cancer
09/26/2024
Alexander I. Spira, MD, PhD, discusses significant unmet needs in the treatment and management of non–small cell lung cancer (NSCLC).
Alexander I. Spira, MD, PhD, discusses significant unmet needs in the treatment and management of non–small cell lung cancer (NSCLC).
Alexander I. Spira, MD, PhD,...
09/26/2024
First Report Managed Care
Videos
Treatment Options for NSCLC: A Discussion on Coverage, Clinical Outcomes, and Payer Perspectives
09/25/2024
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Learn about research...
09/25/2024
First Report Managed Care
Title Card
Videos
Addressing the Root Cause of a Common Ocular Condition: A Virtual Roundtable
09/04/2024
View a roundtable discussion on Demodex blepharitis, a prevalent ocular condition that often goes undiagnosed in patients.
View a roundtable discussion on Demodex blepharitis, a prevalent ocular condition that often goes undiagnosed in patients.
View a roundtable discussion on...
09/04/2024
First Report Managed Care
Jordan Bazinsky
Videos
Addressing Health Disparities and Promoting Equity: The Role of Advanced Imaging Solutions
08/15/2024
Guest expert Jordan Bazinsky discusses the challenges facing the medical imaging industry, the potential of AI and emerging technologies, the role of advanced imaging solutions in promoting health equity, and the key trends and challenges...
Guest expert Jordan Bazinsky discusses the challenges facing the medical imaging industry, the potential of AI and emerging technologies, the role of advanced imaging solutions in promoting health equity, and the key trends and challenges...
Guest expert Jordan Bazinsky...
08/15/2024
First Report Managed Care
Farrukh Awan, MD
Videos
Promising Therapies and Clinical Trials for Chronic Lymphocytic Leukemia
08/14/2024
Farrukh Awan, MD, highlights promising therapies and clinical trials within the field of chronic lymphocytic leukemia (CLL).
Farrukh Awan, MD, highlights promising therapies and clinical trials within the field of chronic lymphocytic leukemia (CLL).
Farrukh Awan, MD, highlights...
08/14/2024
Journal of Clinical Pathways
Hayward
Videos
Evolving Health Care Contact Centers Into Drivers of Value-Based Care
07/31/2024
Discover how health care contact centers can transform into drivers of value-based care through AI, automation, upskilling agents, and rethinking workflows and metrics to improve patient outcomes and population health.
Discover how health care contact centers can transform into drivers of value-based care through AI, automation, upskilling agents, and rethinking workflows and metrics to improve patient outcomes and population health.
Discover how health care contact...
07/31/2024
First Report Managed Care
Lucille Accetta Headshot
Videos
Enhancing Patient Medication Adherence: Insights and Strategies From Asembia 2024
06/11/2024
Lucille Accetta, PharmD, MBA, MSPH, Senior Vice President of CVS Specialty Operations
Key stakeholders in the health care industry gathered to discuss prevalent topics at this year's Asembia annual summit. Medication adherence emerged as one of the most talked-about issues. In a session led by Lucille Accetta, PharmD, MBA,...
Key stakeholders in the health care industry gathered to discuss prevalent topics at this year's Asembia annual summit. Medication adherence emerged as one of the most talked-about issues. In a session led by Lucille Accetta, PharmD, MBA,...
Key stakeholders in the health...
06/11/2024
First Report Managed Care
Melissa Andel, Principal, CommonHealth Solutions, LLC
Videos
Navigating the Impact of the Inflation Reduction Act: Implications for Payers, Patients, and Manufacturers
05/24/2024
Melissa Andel, Principal, CommonHealth Solutions, LLC
Learn about the impacts of the Inflation Reduction Act on payers and patients, highlighting the changes in Medicare benefits and drug coverage coming in 2025 and 2026.
Learn about the impacts of the Inflation Reduction Act on payers and patients, highlighting the changes in Medicare benefits and drug coverage coming in 2025 and 2026.
Learn about the impacts of the...
05/24/2024
First Report Managed Care

Subscribe to our eNewsletters!

First Report Managed Care Newsletter

September 2013 Volume 10 Issue 9

View Issue Archive
Editorial Correspondence

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use